Dentons announced today its representation of long-time client, iCAD, Inc. (NASDAQ: ICAD), in its definitive merger agreement with RadNet, Inc. (NASDAQ: RDNT). iCAD will be acquired by RadNet via an all stock transaction, valued at approximately $103 million, based on iCAD’s closing stock price on April 14, 2025. Through this acquisition, iCAD will be integrated into RadNet’s DeepHealth portfolio of solutions. iCAD’s commercial and engineering team is anticipated to join DeepHealth, accelerating RadNet’s growth. The transaction is expected to close in the third quarter of 2025.

Dentons’ multidisciplinary team is serving as iCad’s legal counsel, led by venture technology and emerging growth partners Jeffrey A. Baumel, Ilan Katz and Ira L. Kotel; with support from venture technology and emerging growth associates Grant Levine, Michael Rosenbloom, Zachary Weiss, Brennan Power and Margaux Bouchet. Also advising on the transaction are pension, benefits and executive compensation partner Michael R. Maryn; tax partner Linda Pfatteicher; venture technology partner Joel N. Bock; and securities litigation partner Kenneth J. Pfaehler.

iCAD’s leading and clinically proven AI-powered breast health solutions will enhance and complement RadNet’s AI-powered cancer detection focused on improving the accuracy and early detection of breast cancer.

About Dentons

Redefining possibilities. Together, everywhere. For more information visit dentons.com